(19)
(11) EP 3 983 789 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.09.2024 Bulletin 2024/37

(45) Mention of the grant of the patent:
31.07.2024 Bulletin 2024/31

(21) Application number: 20737543.7

(22) Date of filing: 12.06.2020
(51) International Patent Classification (IPC): 
G01N 27/48(2006.01)
G01N 30/00(2006.01)
 G01N 33/487(2006.01)
(52) Cooperative Patent Classification (CPC):
G01N 27/48; G01N 33/48714
(86) International application number:
PCT/IB2020/055545
(87) International publication number:
WO 2020/250200 (17.12.2020 Gazette 2020/51)

(54)

METHOD FOR DETERMINING THE CONCENTRATION OF 4-[(4-METHYL-1- PIPERAZINYL)METHYL]-N-(4-METHYL-3-{[4-(3-PYRIDINYL)-2- PYRIMIDINYL] - AMINO} PHENYL)BENZ AMIDE (IMATINIB) IN PLASMA SAMPLES

VERFAHREN ZUR BESTIMMUNG DER KONZENTRATION VON 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-(4-METHYL-3-{[4-(3-PYRIDINYL)-2-PYRIMIDINYL]-AMINO}PHENYL)BENZAMID (IMATINIB) IN PLASMAPROBEN

PROCÉDÉ DE DÉTERMINATION DE LA CONCENTRATION EN 4-[(4-MÉTHYL-1-PIPÉRAZINYL)MÉTHYL]-N-(4-MÉTHYL-3-{[4-(3-PYRIDINYL)-2-PYRIMIDINYL]-AMINO}PHÉNYL)BENZAMIDE (IMATINIB) DANS DES ÉCHANTILLONS DE PLASMA

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 13.06.2019 IT 201900008808

(43) Date of publication of application:
20.04.2022 Bulletin 2022/16

(73) Proprietor: Centro Di Riferimento Oncologico
33081 Aviano (IT)

(72) Inventors:
  • BONAZZA, Gregorio
    30135 Venezia (IT)
  • DANIELE, Salvatore
    35137 Padova (IT)
  • POLO, Federico
    31030 Castelcucco (IT)
  • TOFFOLI, Giuseppe
    33077 Sacile (IT)
  • TARTAGGIA, Stefano
    31039 Riese Pio X (IT)

(74) Representative: Palladino, Saverio Massimo et al
Notarbartolo & Gervasi S.p.A. Viale Achille Papa, 30
20149 Milano
20149 Milano (IT)


(56) References cited: : 
WO-A1-00/67011
 US-A1- 2018 136 161
   
  • E. HAMMAM: "Voltammetric behavior and quantification of the anti-leukemia drug imatinib in bulk form, pharmaceutical formulation, and human serum at a mercury electrode", CANADIAN JOURNAL OF CHEMISTRY, vol. 82, no. 7, 1 January 2004 (2004-01-01), pages 1203 - 1209, XP055662178
  • RODRIGUEZ J ET AL: "Voltammetric determination of Imatinib (Gleevec) and its main metabolite using square-wave and adsorptive stripping square-wave techniques in urine samples", TALANTA, ELSEVIER, AMSTERDAM, NL, vol. 66, no. 1, 31 March 2005 (2005-03-31), pages 202 - 209, XP027860161, ISSN: 0039-9140, [retrieved on 20050331]
  • JUANA RODRÍGUEZ ET AL: "Electrochemical sensor for leukemia drug imatinib determination in urine by adsorptive striping square wave voltammetry using modified screen-printed electrodes", ELECTROCHIMICA ACTA, vol. 269, 1 April 2018 (2018-04-01), AMSTERDAM, NL, pages 668 - 675, XP055663378, ISSN: 0013-4686, DOI: 10.1016/j.electacta.2018.03.051
  • EVA KRALJ ET AL: "Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS., vol. 903, 1 August 2012 (2012-08-01), NL, pages 150 - 156, XP055663385, ISSN: 1570-0232, DOI: 10.1016/j.jchromb.2012.07.011
  • DAVIES A ET AL: "Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography", LEUKEMIA RESEARCH, NEW YORK,NY, US, vol. 34, no. 6, 1 June 2010 (2010-06-01), pages 702 - 707, XP027015257, ISSN: 0145-2126, [retrieved on 20091209]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).